Skip to main content
. Author manuscript; available in PMC: 2022 Jun 13.
Published in final edited form as: Mol Pharm. 2009 May-Jun;6(3):790–800. doi: 10.1021/mp9000712

Figure 3.

Figure 3.

(a) Binding of PSMA-targeted radiotracers containing different spacers to PSMA-positive human prostate cancer cells (LNCaP) in culture. (b) Competitive inhibition of the binding of the 3 best DUPA conjugates (compounds 4, 5, and 6) with excess PMPA is shown in the middle panel. This nearly quantitative competition demonstrates that DUPA conjugate binding is highly specific. (c) Binding of compound 5 to cultured LNCaP cells for 1 h at 4 and 37 °C was compared as a means of assessing the rate of internalization of the DUPA-targeted conjugate. Error bars represent SD (n = 3).